Daratumumab depletes CD38(+) immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Daratumumab targets CD38-expressing myeloma cells through a variety of immune-mediated mechanisms (complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis) and direct apoptosis with crosslinking. These mechanisms may also target...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Krejcik, Jakub, Casneuf, Tineke, Nijhof, Inger S., Verbist, Bie, Bald, Jaime, Plesner, Torben, Syed, Khaja, Liu, Kevin, van de Donk, Niels W. C. J., Weiss, Brendan M., Ahmadi, Tahamtan, Lokhorst, Henk M., Mutis, Tuna, Sasser, A. Kate
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2016
Matèries:
Immunobiology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4957162/
https://ncbi.nlm.nih.gov/pubmed/27222480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-12-687749
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars